{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T19:40:07Z","timestamp":1769456407668,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Typhoid Vaccine Acceleration Consortium","award":["OPP1151153"],"award-info":[{"award-number":["OPP1151153"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1151153"],"award-info":[{"award-number":["OPP1151153"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Typhoid fever illnesses are responsible for more than 100 000 deaths worldwide each year. In Bangladesh, typhoid fever is endemic, with incidence rates between 292\u2013395 per 100 000 people annually. While considerable effort has been made to improve access to clean water and sanitation services in the country, there is still a significant annual typhoid burden, which particularly affects children. A typhoid conjugate vaccine (Vi-TCV) was recently prequalified by the World Health Organization and recommended for use, and offers the potential to greatly reduce the typhoid burden in Bangladesh.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study is a double-blind, cluster-randomized, controlled trial of Vi-TCV in a geographically defined area in Dhaka, Bangladesh. At least 32 500 children from 9 months to &amp;lt;16 years of age will be vaccinated and followed for 2 years to assess the effectiveness and safety of Vi-TCV in a real-world setting. All cluster residents will also be followed to measure the indirect effect of Vi-TCV in this community.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and Dissemination<\/jats:title><jats:p>This protocol has been approved by the International Centre for Diarrhoeal Disease Research, Bangladesh; a University of Oxford research review; and both ethical review committees. Informed written consent and assent will be obtained before enrollment. Vi-TCV has been shown to be safe and effective in previous, smaller-scale studies. The results of this study will be shared through a series of peer-reviewed journal articles. The findings will also be disseminated to the local government, stakeholders within the community, and the population within which the study was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This trial is the largest and only cluster-randomized control trial of Vi-TCV ever conducted, and will describe the effectiveness of Vi-TCV in an endemic population. The results of this trial may provide important evidence to support the introduction of TCVs in countries with a high burden of typhoid.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trials Registration<\/jats:title><jats:p>ISRCTN11643110.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciy1107","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T03:33:10Z","timestamp":1547004790000},"page":"S74-S82","source":"Crossref","is-referenced-by-count":31,"title":["Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial"],"prefix":"10.1093","volume":"68","author":[{"given":"Katherine","family":"Theiss-Nyland","sequence":"first","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firdausi","family":"Qadri","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research\u2013Bangladesh, Dhaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Colin-Jones","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Zaman","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research\u2013Bangladesh, Dhaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhana","family":"Khanam","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research\u2013Bangladesh, Dhaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxue","family":"Liu","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merryn","family":"Voysey","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arifuzzaman","family":"Khan","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research\u2013Bangladesh, Dhaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazmul","family":"Hasan","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research\u2013Bangladesh, Dhaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahim","family":"Ashher","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research\u2013Bangladesh, Dhaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yama G","family":"Farooq","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Pollard","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D","family":"Clemens","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research\u2013Bangladesh, Dhaka"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"2019121022403284000_CIT0001","first-page":"346","article-title":"The global burden of typhoid fever","volume":"82","author":"Cru1mp","year":"2004","journal-title":"Bull World Health Organ"},{"key":"2019121022403284000_CIT0002","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/adc.75.3.214","article-title":"Impact of age and drug resistance on mortality in typhoid fever","volume":"75","author":"Bhutta","year":"1996","journal-title":"Arch Dis Child"},{"key":"2019121022403284000_CIT0003","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4269\/ajtmh.2000.62.644","article-title":"The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam","volume":"62","author":"Lin","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"2019121022403284000_CIT0004","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0140-6736(91)91910-M","article-title":"Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine","volume":"338","author":"Simanjuntak","year":"1991","journal-title":"Lancet"},{"key":"2019121022403284000_CIT0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0140-6736(98)09001-1","article-title":"Typhoid fever in children aged less than 5 years","volume":"354","author":"Sinha","year":"1999","journal-title":"Lancet"},{"key":"2019121022403284000_CIT0006","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/cid\/cix229","article-title":"An appraisal of the clinical features of pediatric enteric fever: systematic review and meta-analysis of the age-stratified disease occurrence","volume":"64","author":"Britto","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019121022403284000_CIT0007","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(05)67181-4","article-title":"Typhoid and paratyphoid fever","volume":"366","author":"Bhan","year":"2005","journal-title":"Lancet"},{"key":"2019121022403284000_CIT0008","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.ijid.2009.11.023","article-title":"Burden of typhoid and paratyphoid fever in a densely populated urban community, Dhaka, Bangladesh","volume":"14","author":"Naheed","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2019121022403284000_CIT0009","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3201\/eid1102.040422","article-title":"Bacteremic typhoid fever in children in an urban slum, Bangladesh","volume":"11","author":"Brooks","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"2019121022403284000_CIT0010","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale","year":"2014","journal-title":"Lancet Glob Health"},{"key":"2019121022403284000_CIT0011","volume-title":"Off-track, off-target; why investment in water, sanitation and hygiene is not reaching those who need it most","year":"2011"},{"key":"2019121022403284000_CIT0012"},{"key":"2019121022403284000_CIT0013","first-page":"49","article-title":"Typhoid vaccines: WHO position paper","volume":"83","year":"2008","journal-title":"Wkly Epidemiol Rec"},{"key":"2019121022403284000_CIT0014","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.vaccine.2009.11.051","article-title":"Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever","volume":"28","author":"Froeschle","year":"2010","journal-title":"Vaccine"},{"key":"2019121022403284000_CIT0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10654-005-7454-6","article-title":"Outbreak of typhoid fever in vaccinated members of the French Armed Forces in the Ivory Coast","volume":"20","author":"Michel","year":"2005","journal-title":"Eur J Epidemiol"},{"key":"2019121022403284000_CIT0016","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1146\/annurev.iy.13.040195.003255","article-title":"T cell-independent antigens type 2","volume":"13","author":"Mond","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"2019121022403284000_CIT0017","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/j.carres.2003.07.008","article-title":"Immunology of bacterial polysaccharide antigens","volume":"338","author":"Weintraub","year":"2003","journal-title":"Carbohydr Res"},{"key":"2019121022403284000_CIT0018","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/infdis\/166.2.451","article-title":"Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children","volume":"166","author":"Olanratmanee","year":"1992","journal-title":"J Infect Dis"},{"key":"2019121022403284000_CIT0019","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/IAI.61.3.1149-1151.1993","article-title":"Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children","volume":"61","author":"Cryz","year":"1993","journal-title":"Infect Immun"},{"key":"2019121022403284000_CIT0020","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"key":"2019121022403284000_CIT0021","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/CVI.00532-10","article-title":"The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines","volume":"18","author":"Thiem","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2019121022403284000_CIT0022","unstructured":"World Health Organization. Typbar TCV from Bharat Biotech, world\u2019s first typhoid conjugate vaccine prequalified by WHO. 2018. Available at: http:\/\/www.who.int\/medicines\/news\/2017\/Bharat-Biotech-TypbarTCV-WHO-PQ-Press-Release-Global-Final.pdf?ua=1. Accessed 17 July 2018."},{"key":"2019121022403284000_CIT0023","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"2019121022403284000_CIT0024","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/cid\/cix1145","article-title":"Seroefficacy of Vi Polysaccharide\u2013tetanus toxoid typhoid conjugate vaccine (Typbar TCV)","volume":"67","author":"Voysey","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019121022403284000_CIT0025","first-page":"153","article-title":"Typhoid vaccine: WHO position paper - March 2018","volume":"13","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"2019121022403284000_CIT0026","unstructured":"Gavi The Vaccine Alliance. Typhoid conjugate vaccine support window. Available at: http:\/\/www.gavi.org\/About\/Governance\/Gavi-Board\/Minutes\/2014\/10-December\/ (Accessed 31 July 2018)."},{"key":"2019121022403284000_CIT0027","doi-asserted-by":"crossref","first-page":"e016283","DOI":"10.1136\/bmjopen-2017-016283","article-title":"The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys","volume":"7","author":"Darton","year":"2017","journal-title":"BMJ Open"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/Supplement_2\/S74\/28024004\/ciy1107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/Supplement_2\/S74\/28024004\/ciy1107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T02:07:12Z","timestamp":1606010832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/Supplement_2\/S74\/5371233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":27,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2019,3,7]]},"published-print":{"date-parts":[[2019,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy1107","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,15]]},"published":{"date-parts":[[2019,3,7]]}}}